Tissue-Specific Human Extracellular Matrix Scaffolds Promote Pancreatic Tumour Progression and Chemotherapy Resistance

The potential of carbohydrate supramolecular hydrogels for long-term 3D culture of primary fibroblasts

N-Alkyl-galactonamides, which are small synthetic molecules derived from galactose, self-assemble to give fibrous hydrogels. These molecules are biocompatible and, in a previous study, the cell culture of human neural stem cells was performed for 7 days on a gel of N-heptyl-D-galactonamide. With the objective of broadening the scope of these molecules as scaffolds for cell culture, in the present study, the culture of primary human dermal fibroblasts has been carried out on N-nonyl-D-galactonamide hydrogels. These supramolecular fibrillar hydrogels have a sufficient mechanical strength to withstand cell culture (≈50 kPa) and they are resistant enough on the long term to carry out the cell culture over at least 3 weeks. In contrast to N-heptyl-D-galactonamide, N-nonyl-D-galactonamide is insoluble in the culture medium. It avoids its dissolution at each renewal of the culture medium. The molecule is only slowly eliminated by other mechanisms (1/3rd in 3 weeks), which did not impair the cell culture on a monthly scale. The hydrogel's microstructure and how the cells organize on this scaffold have been studied using electron and two-photon microscopies. The gel is made of a quite homogeneous network with a width of ≈180 nm and hundreds of micrometer long fibers, except at the surface where a dense mat of heterogeneous fibers is formed. We focused on methods able to colocalize the cells and the gel fibers. Many cell clusters have elongated and multidirectionnal shapes, guided by the fibers. Chains of single cells are also found following the fibers from one cluster to another. N-Nonyl-D-galactonamide fibers, which have the advantage of not being autofluorescent, do not mask the fluorescence of cells. But interestingly, they give a strong second harmonic generation (SHG) signal, due to their well-organized lamellar structure. We also made a special effort to visualize the penetration of cells within the depth of the hydrogels, in 3D, notably by sectioning the hydrogels, despite their softness. It was found that most of the cells stayed at the surface, but several cells grew within the supramolecular fiber network between 50 and 100 μm depth.

HLA Awareness in tissue decellularization: A paradigm shift for enhanced biocompatibility, studied on the model of the human fascia lata graft

Last twenties, tissue engineering has rapidly advanced to address the shortage of organ donors. Decellularization techniques have been developed to mitigate immune rejection and alloresponse in transplantation. However, a clear definition of effective decellularization remains elusive. This study compares various decellularization protocols using the human fascia lata model. Morphological, structural and cytotoxicity/viability analyses indicated that all the five tested protocols were equivalent and met Crapo's criteria for successful decellularization. Interestingly, only the in vivo immunization test on rats revealed differences. Only one protocol exhibited Human Leucocyte Antigen (HLA) content below 1% residual threshold, the only criterion preventing rat immunization with an absence of rat anti-human IgG switch after one month (N=4 donors for each of the 7 groups, added by negative and positive controls, n=28). By respecting a refined set of criteria, i.e. lack of visible nuclear material, <50ng DNA/mg dry weight of extracellular matrix, and <1% residual HLA content, the potential for adverse host reactions can be drastically reduced. In conclusion, this study emphasizes the importance of considering not only nuclear components but also major histocompatibility complex in decellularization protocols and proposes new guidelines to promote safer clinical development and use of bioengineered scaffolds.

Current Advances in the Use of Tissue Engineering for Cancer Metastasis Therapeutics

Cancer is a leading cause of death worldwide and results in nearly 10 million deaths each year. The global economic burden of cancer from 2020 to 2050 is estimated to be USD 25.2 trillion. The spread of cancer to distant organs through metastasis is the leading cause of death due to cancer. However, as of today, there is no cure for metastasis. Tissue engineering is a promising field for regenerative medicine that is likely to be able to provide rehabilitation procedures to patients who have undergone surgeries, such as mastectomy and other reconstructive procedures. Another important use of tissue engineering has emerged recently that involves the development of realistic and robust in vitro models of cancer metastasis, to aid in drug discovery and new metastasis therapeutics, as well as evaluate cancer biology at metastasis. This review covers the current studies in developing tissue-engineered metastasis structures. This article reports recent developments in in vitro models for breast, prostate, colon, and pancreatic cancer. The review also identifies challenges and opportunities in the use of tissue engineering toward new, clinically relevant therapies that aim to reduce the cancer burden.

Bioengineering Approaches for the Pancreatic Tumor Organoids Research and Application

Pancreatic cancer is a highly lethal form of digestive malignancy that poses significant health risks to individuals worldwide. Chemotherapy-based comprehensive treatment is the primary therapeutic approach for midlife and late-life patients. Nevertheless, the heterogeneity of the tumor and individual genetic backgrounds result in substantial variations in drug sensitivity among patients, rendering a single treatment regimen unsuitable for all patients. Conventional pancreatic cancer tumor organoid models are capable of emulating the biological traits of pancreatic cancer and are utilized in drug development and screening. However, these tumor organoids can still not mimic the tumor microenvironment (TME) in vivo, and the poor controllability in the preparation process hinders translation from essential drug screening to clinical pharmacological therapy. In recent years, many engineering methods with remarkable results have been used to develop pancreatic cancer organoid models, including bio-hydrogel, co-culture, microfluidic, and gene editing. Here, this work summarizes and analyzes the recent developments in engineering pancreatic tumor organoid models. In addition, the future direction of improving engineered pancreatic cancer organoids is discussed for their application prospects in clinical treatment.

Extracellular Vesicles: New Classification and Tumor Immunosuppression

Extracellular vesicles (EVs) are cell-derived membrane-surrounded vesicles carrying various types of molecules. These EV cargoes are often used as pathophysiological biomarkers and delivered to recipient cells whose fates are often altered in local and distant tissues. Classical EVs are exosomes, microvesicles, and apoptotic bodies, while recent studies discovered autophagic EVs, stressed EVs, and matrix vesicles. Here, we classify classical and new EVs and non-EV nanoparticles. We also review EVs-mediated intercellular communication between cancer cells and various types of tumor-associated cells, such as cancer-associated fibroblasts, adipocytes, blood vessels, lymphatic vessels, and immune cells. Of note, cancer EVs play crucial roles in immunosuppression, immune evasion, and immunotherapy resistance. Thus, cancer EVs change hot tumors into cold ones. Moreover, cancer EVs affect nonimmune cells to promote cellular transformation, including epithelial-to-mesenchymal transition (EMT), chemoresistance, tumor matrix production, destruction of biological barriers, angiogenesis, lymphangiogenesis, and metastatic niche formation.